Hypertension tied to poorer survival in tuberculosis
29 Oct 2020
Tuberculosis (TB) patients with high blood pressure are at increased risk of death during the 9 months following initiation of treatment, a study has found. But the good news is that dihydropyridine calcium channel blockers (DHP-CCBs) may improve survival outcomes.
Contents : Per 100 u/mL + 50 mcg/mL soln for inj (10-40 pen) Insulin glargine 3.64 mg (equiv to 100 u), lixisenatide 50 mcg. Per 100 u/mL + 33 mcg/mL soln for inj (30-60 pen) Insulin glargine 3.64 mg (equiv to 100 u), lixisenatide 33 mcg
Indications/Uses : In combination w/ metformin for adults w/ type 2 DM to improve glycaemic control when metformin alone, or metformin combined w/ another oral glucose lowering drugs, or w/ basal insulin does not provide adequate glycaemic control.
Indications/Uses : Advanced prostate cancer in combination w/ luteinizing hormone-releasing hormone (LHRH) analogue therapy or surgical castration. Monotherapy or as adjuvant to radical prostatectomy or radiotherapy in patients w/ locally advanced prostate cancer at high risk for disease progression.
Indications/Uses : Amebiasis; urogenital trichomoniasis; non-specific vaginitis; giardiasis. Curative treatment of medico-surgical infections due to susceptible anaerobic pathogens. Prophylaxis against infections caused by susceptible anaerobic pathogens in high risk surgical contexts. Conversion from prophylactic or curative injectable treatment of infections due to susceptible anaerobic pathogens.
Indications/Uses : Treatment of community-acquired pneumonia, UTI including complicated UTI, skin & soft tissue infections. Tab: Treatment of adults >18 yr w/ mild, moderate & severe infections caused by susceptible strains of microorganisms in the following diseases: Nosocomial pneumonia, acute bacterial exacerbation of chronic bronchitis, acute maxillary sinusitis, chronic bacterial prostatitis; mild to moderate uncomplicated skin & skin structure infections, acute pyelonephritis & uncomplicated UTI.
Indications/Uses : Control of serum P in patients w/ chronic kidney disease (CKD) on dialysis; hyperphosphatemia in adults receiving hemo- or peritoneal dialysis. Adult CKD patients not on dialysis w/ serum P >1.78 mmol/L (5.5 mg/dL). Powd for susp: Control of serum P in ped patients (>6 yr & BSA of >0.75 m2) w/ CKD.
Indications/Uses : Induction & augmentation of labor, to control postpartum bleeding & uterine hypotonicity in 3rd stage of labor. Promote lactation in cases of faulty milk ejection.
Sign Out
